ReviewMicromachines2026
Microfluidic and Paper-Based Recombinase Polymerase Amplification Systems for Decentralized Diagnostics and Biosurveillance.
Review in Micromachines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapid Visual Detection of Cyprinid Herpesvirus 2 Based on One-Tube RPA-CRISPR/Cas12a System.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinase polymerase amplification (RPA) has become a central amplification strategy for decentralized molecular diagnostics because it operates rapidly at mild temperatures and requires far less thermal control than PCR. Its analytical value increases substantially when paired with microfluidic and paper-based platforms, where sample handling, reagent delivery, amplification, and signal readout can be organized within compact, low-power, and field-compatible formats. This review examines recent progress in microfluidic and paper-based RPA systems across biomedical diagnostics, food safety testing, environmental monitoring, and One Health biosurveillance. Particular attention is given to integrated device architectures, including centrifugal chips, capillary-driven platforms, microfluidic paper-based analysis devices (μPADs), electrochemical biosensors, CRISPR-assisted assays, digital microfluidic systems, and sample-to-answer cartridges. Biomedical applications now span respiratory viruses, reproductive and emerging infections, bacterial and parasitic diseases, pharmacogenomic markers, and cancer-related biomarkers. RPA-enabled platforms are moving steadily into food safety and environmental surveillance, covering pathogen detection, seafood and dairy monitoring, agricultural disease control, antimicrobial-resistance tracking, and airborne pathogen screening. At the same time, the field is shifting toward more intelligent diagnostic formats. Smartphone imaging, artificial intelligence (AI)-assisted interpretation, digital partitioning, cloud connectivity, and automated quality control are increasingly being built into rapid testing workflows, giving these systems greater portability, consistency, and decision-making value. Despite this progress, practical deployment still depends on robust sample preparation, multiplex stability, quantitative reliability, reagent storage, scalable fabrication, and regulatory validation. Continued convergence of RPA chemistry with microfluidics, paper devices, CRISPR recognition, electrochemical readout, and data-assisted interpretation is expected to support more robust and accessible molecular diagnostic workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.